By Tom Winnifrith & Steve Moore | Saturday 16 January 2021
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Making SkinBioTherapeutics (SBTX) one of our three tips of the year 2021, we noted we considered it likely to make 2021 a breakthrough year, including with a planned first quarter human study for AxisBiotix™ targeting psoriasis and then, subject to a positive readout, commencing commercialisation. Already we now have an “Enrolment for AxisBiotix-PsT study commences” announcement and the shares are already massively higher than our 15.5p tip price at 29p. But you’d be mad to sell.
Already registered? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen